Riskpilot← Back to searchSign inGet full accessDraupnir Bio ApS
APSActiveCVR 38546880Nordre Fasanvej 215Research and experimental development on natural sciences and engineering · NACE 7210Est. 201710 employeeswww.draupnir.bio
Revenue 2024
—
EBITDA margin
—
+1% vs 2023
Equity ratio
78.9%
Financial strength
Net profit 2024
DKK -40,3M
+2% vs 2023
| Revenue | — | — |
| EBITDA | DKK -43,8M | +1% |
| Net profit | DKK -40,3M | +2% |
| Total assets | DKK 35M | -3% |
| Equity | DKK 27,6M | -6% |
| Employees | 10 | — |
Legal name
Draupnir Bio ApS
CVR number
38546880
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
4. april 2017
Share capital
DKK 1.279.717
Employees
10 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsesformanden i forening med et bestyrelsesmedlem, eller af bestyrelsesformanden i forening med en direktør eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at forske i, udvikle, producere og sælge bioteknologiske produkter og medicinalprodukter samt anden virksomhed, der efter bestyrelsens skøn er forbundet dermed.
Address
Nordre Fasanvej 215
Phone
+4551500560
Email
dannemann@draupnir.bio
Website
www.draupnir.bio
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -65 | -1.779 | -15.910 | — | — | — | — | — |
| Staff expenses | -0 | -0 | -1.842 | -19.622 | -23.292 | -22.795 | -17.104 | -21.224 |
| EBITDA | -65 | -1.779 | -17.752 | -65.614 | -69.985 | -42.607 | -44.023 | -43.751 |
| Depreciation & amort. | -0 | -508 | -0 | -117 | -1.767 | -2.430 | -2.413 | -2.398 |
| EBIT | -65 | -2.288 | -17.752 | -65.731 | -71.752 | -45.037 | -46.436 | -46.149 |
| Net financials | -6 | -91 | -798 | -389 | -665 | -449 | -81 | 406 |
| Profit before tax | -71 | -2.378 | -18.549 | -66.120 | -72.417 | -45.486 | -46.518 | -45.743 |
| Tax | -0 | -261 | -3.355 | -5.500 | -5.373 | -5.596 | -5.352 | -5.430 |
| Net profit | -71 | -2.118 | -15.194 | -60.620 | -67.044 | -39.890 | -41.166 | -40.314 |
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 709 | 4.582 | 53.395 | 60.790 | 67.865 | 28.383 | 36.192 | 35.033 |
| Equity | 229 | -1.789 | 51.974 | 54.225 | 53.466 | 18.566 | 29.386 | 27.633 |
| Long-term debt | 0 | 5.060 | 0 | 394 | 3.766 | 2.632 | 1.416 | 112 |
| Short-term debt | 480 | 1.311 | 1.421 | 6.172 | 8.987 | 7.185 | 5.390 | 7.287 |
| Total debt | 480 | 6.371 | 1.421 | 6.566 | 12.753 | 9.817 | 6.806 | 7.399 |
EBITDA margin
-4375100000.0%
This company
15.8%
Market median
-27690506429% vs market
20172024
Equity ratio
78.9%
This company
38.2%
Market median
+107% vs market
20172024
Return on equity
-145.9%
This company
18.4%
Market median
-893% vs market
20172024
Net profit margin
-4031400000.0%
This company
8.1%
Market median
-49770370470% vs market
20172024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20172024
Debt / equity
0.27×
This company
0.62×
Market median
+56% vs market
20172024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-04-04 – 2017-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AT Management | Management | 2021 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2017 | — | — | |
| Board of Directors | 2019 | — | — | |
| Board of Directors | 2019 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2017 | — | — | |
| Board of Directors | 2019 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2018 | — | — | |
| Chairman | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Novo Holdings A/S | Company | 20.0% | 20.0% | 2024 |
| Individual | 20.0% | 20.0% | 2024 | |
| Individual | 20.0% | 20.0% | 2024 | |
Danmarks Eksport- og Investeringsfond | Company | 10.0% | 10.0% | 2024 |
| Individual | 10.0% | 10.0% | 2024 | |
| Individual | 5.0% | 5.0% | 2019 | |
| Individual | 5.0% | 5.0% | 2019 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
NOVO NORDISK FONDEN
Draupnir Bio ApS Board members of Draupnir Bio ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Andrew Thomas Hotchkiss | Management | 0 companies |
| Peder Søndergaard Madsen | Chairman | 0 companies |
| Stefan Emanuel Luzi | Board of Directors | 0 companies |
| Fiona MacLaughlin | Board of Directors | 0 companies |
| Ivan Burkov | Board of Directors | 0 companies |
| Emmanuelle Coutanceau | Board of Directors | 0 companies |
| Camilla Gustafsen | Board of Directors | 0 companies |
| Simon Glerup Pedersen | Board of Directors | 0 companies |
| Roel Bulthuis | Board of Directors | 0 companies |
| Robert Andrew Donald Scott | Board of Directors | 0 companies |
| Peter Hans Andreas Seeberger | Board of Directors | 0 companies |
| Eva-Lotta Coulter | Chairman | 0 companies |